2. Academic Validation
  3. Indole Glucocorticoid Receptor Antagonists Active in a Model of Dyslipidemia Act via a Unique Association with an Agonist Binding Site

Indole Glucocorticoid Receptor Antagonists Active in a Model of Dyslipidemia Act via a Unique Association with an Agonist Binding Site

  • J Med Chem. 2015 Aug 27;58(16):6607-18. doi: 10.1021/acs.jmedchem.5b00736.
John G Luz 1,  Matthew W Carson 2,  Bradley Condon 1,  David Clawson 2,  Anna Pustilnik 1,  Daniel T Kohlman 2,  Robert J Barr 2,  James S Bean 2,  M Joelle Dill 2,  Dana K Sindelar 2,  Milan Maletic 1,  Michael J Coghlan 2
Affiliations

Affiliations

  • 1 Eli Lilly Biotechnology Center , 10300 Campus Point Drive, Suite 200, San Diego, California 92121 United States.
  • 2 Lilly Research Laboratories, A Division of Eli Lilly & Co. , Lilly Corporate Center, Indianapolis, Indiana 46285 United States.
PMID: 26218343 DOI: 10.1021/acs.jmedchem.5b00736
Abstract

To further elucidate the structural activity correlation of Glucocorticoid Receptor (GR) antagonism, the crystal structure of the GR ligand-binding domain (GR LBD) complex with a nonsteroidal antagonist, compound 8, was determined. This novel indole sulfonamide shows in vitro activity comparable to known GR antagonists such as mifepristone, and notably, this molecule lowers LDL (-74%) and raises HDL (+73%) in a hamster model of dyslipidemia. This is the first reported crystal structure of the GR LBD bound to a nonsteroidal antagonist, and this article provides additional elements for the design and pharmacology of clinically relevant nonsteroidal GR antagonists that may have greater selectivity and fewer side effects than their steroidal counterparts.

Figures